HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment

The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with gliobl...

Full description

Saved in:
Bibliographic Details
Published inSeminars in oncology Vol. 45; no. 1-2; pp. 27 - 33
Main Authors Bello-Rivero, Iraldo, Garcia-Vega, Yanelda, Duncan-Roberts, Yaquelin, Vazquez-Blomquistc, Dania, Santana-Milian, Hector, Besada-Perez, Vladimir, Rios-Cabrera, Margarita
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2018
Subjects
brain tumor
HeberFERON
renal carcinoma
skin cancer
skin cancer
brain tumor
HeberFERON
renal carcinoma
Online AccessGet full text

Cover

More Information
Summary:The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0093-7754
1532-8708
DOI:10.1053/j.seminoncol.2018.04.007